The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were […]readmore
Tags : Reata
1. Johnson & Johnson Initiates Voluntarily Recall of a Single Lot of its Baby Powder in the US Published: Oct 18, 2019 | Tags: JnJ, Initiates, Voluntarily, Recall, Baby Powder, US […]readmore
Shots: The registrational part 2 of the P-II MOXIe study involves assessing of Omaveloxolone (150mg) vs PBO in 103 patients in a ratio (1:1) with FA at 11 sites across […]readmore
OraSure Technologies’ Rapid Diagnostic OraQuick Ebola Rapid Antigen Test Receives the US FDA Marketing Approval for Detection of Ebola Virus Antigens Published: Oct 10, 2019 | Tags: Diagnostic, Oraquick Ebola Rapid […]readmore
Shots: AbbVie to receive $330M in cash primarily for bardoxolone, $75M up front in 2019 and the remaining value payable in installments in Q2 and Q4 2020 plus royalties on […]readmore